旧版威斯尼斯人下载安装|首頁(歡迎您)

当前位置: 首页 > 师资队伍 > 教师名录 > A > 正文

Andrew Lewis

【来源: | 发布日期:2021-06-15 】

Dr Andrew Lewis

Lecturer in Chemical Biology

·Email addressandrew.lewis@mmu.ac.uk

Who am I?

Originally from Swansea in Wales, Dr Andrew Lewis graduated with his PhD from the University of Cambridge in 2013 under the supervision of Professor Sir Shankar Balasubramanian. During his PhD he worked on the synthesis and biological understanding of quinone containing natural products and their use as anticancer agents. Prior to this, Andrew read Natural Sciences at St Catharine's College, University of Cambridge completing his MSc with Professor Steven Ley working on the synthesis of novel hydrogen bond organocatalysts.

From 2013 to 2016 Andrew worked as a postdoctoral fellow at the University of Toronto with Professor Patrick Gunning working on the design and synthesis of protein-protein interaction inhibitors and using chemical biological techniques to understand their mode of action. After moving back to the UK in 2016 Andrew joined the Huber group at the Target Discovery Institute, University of Oxford where his research involved the use of chemical biology and chemoproteomic techniques to identify novel drug targets for multiple myeloma.

In October 2019 Andrew joined Manchester Metropolitan University as a lecturer in chemical biology where his group focuses on developing chemical tools to understand protein-protein interactions

Academic Biography

Academic and professional qualifications

2008-2012 PhD - CRUK Graduate Training Programme in Medicinal Chemistry, University of Cambridge

Supervisor:Professor Sir Shankar Balasubramanian

2007-2008 MSci Chemistry, University of Cambridge

Supervisor:Professor Steve Ley

Previous employment

2016-2019 Postdoctoral Research Fellow, Target Discovery Institute, University of Oxford

Supervisor:Dr Kilian Huber

2013-2016 Postdoctoral Research Fellow, University of Toronto

Supervisor:Professor Patrick Gunning

Research Expertise, Publications & Grants

Publications

·Journal articles

V. Fagan, C. Johansson, C. Gileadi, O. Monteiro, JE. Dunford,et al.(2019).A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin Function.Journal of Medicinal Chemistry.62(20), pp.9008-9025.

S. Scheer, S. Ackloo, TS. Medina, M. Schapira, F. Li,et al.(2019).A chemical biology toolbox to study protein methyltransferases and epigenetic signaling.Nature Communications.10(1),

J. Stefaniak, AM. Lewis, D. Conole, SRG. Galan, CJR. Bataille,et al.(2018).Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors.ACS Chemical Biology.13(10), pp.2849-2854.

SR. da Silva, S-L. Paiva, M. Bancerz, M. Geletu, AM. Lewis,et al.(2016). A selective inhibitor of the UFM1-activating enzyme, UBA5.Bioorganic & medicinal chemistry letters.26(18), pp.4542-4547.

DP. Ball, AM. Lewis, D. Williams, D. Resetca, DJ. Wilson,et al.(2016). Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent.Oncotarget.7(15), pp.20669-20679.

M. Singh, N. Garg, C. Venugopal, R. Hallett, T. Tokar,et al.(2015). STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation.Oncotarget.6(29), pp.27461-27477.

S. Haftchenary, AO. Jouk, I. Aubry, AM. Lewis, M. Landry,et al.(2015). Identification of Bidentate Salicylic Acid Inhibitors of PTP1B.ACS medicinal chemistry letters.6(9), pp.982-986.

AA. Cumaraswamy, AM. Lewis, M. Geletu, A. Todic, DB. Diaz,et al.(2014).Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein.ACS medicinal chemistry letters.5(11), pp.1202-1206.

BDG. Page, DC. Croucher, ZH. Li, S. Haftchenary, VH. Jimenez-Zepeda,et al.(2013). Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma.Journal of medicinal chemistry.56(18), pp.7190-7200.

·Chapters in books

AM. Lewis, DP. Ball, R. Rana, JS. Park, D. Rosa,et al.(2015). Developing Inhibitors of STAT3: Targeting Downstream of the Kinases for Treating Disease. In:Kinomics. Wiley-VCH Verlag GmbH & Co. KGaA, pp.281-300.

Manchester Met full-time employee and will teach at Manchester Metropolitan Joint Institute, Hubei University.

Baidu
sogou